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ABSTRACT
Objectives The study aim was to explore experiences 
of patients with pleural mesothelioma of follow- up care 
in three National Health Service (NHS) Trusts to develop 
recommendations for practice.
Design The study design was qualitative and comprised 
three interlinked phases: a documentary analysis, 
interviews and consultation meetings. Altheide and 
Johnson’s Analytic Realism theoretical framework guided 
the thematic data analysis process.
Setting The study was conducted in three NHS Trusts in 
South England. Two were secondary care settings and the 
third was a tertiary centre.
Participants The secondary care trusts saw 15–20 
patients with new mesothelioma per year and the tertiary 
centre 30–40. The tertiary centre had a designated 
mesothelioma team. Twenty- one patients met the inclusion 
criteria: >18 years, mesothelioma diagnosis and in follow- 
up care. Non- English speaking participants, those unable 
to provide written informed consent or those whom the 
clinical team felt would find participation too distressing 
were excluded. All participants were white, 71% were 
70–79 years old and 71% were men. Three consultation 
meetings were conducted with key stakeholders 
including mesothelioma nurse specialists, patients with 
mesothelioma, carers and local clinical commissioning 
group members.
Main outcome measures Specific outcomes were to 
gain a detailed understanding of mesothelioma follow- up 
care pathways and processes and to develop coproduced 
recommendations for practice.
Results Mesothelioma pathways were not always distinct 
from lung cancer care pathways. All trusts provided 
follow- up information and resources but there was varied 
information on how to access local support groups, 
research or clinical trial participation. Five themes were 
developed relating to people; processes; places; purpose 
and perception of care. Coproduced recommendations 
for improving mesothelioma follow- up pathways were 
developed following the consultation meetings.
Conclusions This study has developed recommendations 
which identify the need for patients with pleural 
mesothelioma to access consistent, specialist, 
streamlined mesothelioma care, centred around specialist 
mesothelioma nurses and respiratory consultants, with 
input from the wider multidisciplinary team.
INTRODUCTION
Malignant pleural mesothelioma is a rare and 
incurable cancer arising from the pleural 
lining of the lung.1 Its main cause is previous 
occupational or environmental exposure to 
asbestos; this has a 20–50 year latency period.2 
Mesothelioma is a global health concern; 
however, the UK has the highest recorded 
incidence of mesothelioma in the world, with 
~2700 diagnoses per year (approximately 4 
cases per 100 000).3 4 Though this number 
remains relatively small compared with that 
of lung cancer (~47 000),4 the symptom 
burden of mesothelioma is high and is char-
acterised by a poor prognosis and a lack 
of effective treatments. Median survival is 
8–14 months from diagnosis,5 with the only 
Strengths and limitations of this study
 ► To our knowledge, this is the first study to qualita-
tively explore experiences of patients with mesothe-
lioma of follow- up care pathways across different 
hospital trusts; this has enabled comparisons in pa-
tient experience to be mapped out and recommen-
dations developed.
 ► The 21 participants who were interviewed had a 
wide range of demographic characteristics, increas-
ing the transferability of our findings.
 ► The consultation meetings undertaken verified and 
prioritised our study findings, ensuring that any rec-
ommendations developed were practical, feasible 
and of value to patients.
 ► The recommendations were developed using a co-
production approach, with input from healthcare 
professionals, patients, carers and commissioners.
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effective chemotherapy regimen extending this by a 
median of 2.8 months.6 Patients with mesothelioma typi-
cally present with advanced disease and progressive symp-
toms of dyspnoea, chest wall pain, weight loss, sweating 
and fatigue are common.7–10 This results in high levels 
of psychological distress, including depression, anxiety, 
fear, anger and hopelessness being frequently docu-
mented.8 10–16
Recently published British Thoracic Society guide-
lines for the investigation and management of malignant 
pleural mesothelioma recommended that patients with 
mesothelioma should be offered accurate and under-
standable information and the opportunity to discuss 
any concerns about their disease with healthcare profes-
sionals,2 17 as a means of facilitating the highest standards 
of care possible.18 19 However, there is a current lack 
of specialist pleural mesothelioma services to support 
patients with mesothelioma. Though specialist mesothe-
lioma nurses have been introduced in some areas of the 
UK, their small number means that their impact is limited 
as they are unable to reach all patients living with meso-
thelioma.20 In addition, the relatively low numbers of 
new cases of mesothelioma diagnosed each year3 means 
that patients with mesothelioma often enter the same 
follow- up pathways as people with lung cancer, despite 
increasing recognition that their care needs are specific 
to their condition and that specialist services, such as 
mesothelioma multidisciplinary teams, can provide real 
benefit.1–3 12 21 22 Little research has been published on 
the care needs of patients with mesothelioma; however, 
a systematic review comparing the psychological care 
needs of patients with mesothelioma and advanced lung 
cancer12 identified a need for separate assessment and 
care pathways.
Follow- up pathways for patients with mesothelioma 
differ across UK National Health Service (NHS) Trusts, 
with variation in the services they offer. The British 
Thoracic Society guidelines5 suggest 3–4 monthly 
follow- up with an oncologist, respiratory physician or 
specialist nurse according to individual patients’ treat-
ment plans, but no existing national recommendation or 
published research has specifically examined the follow- up 
care pathway. As a result, this study set out to explore 
experiences of patients with pleural mesothelioma of 
follow- up care in three NHS Trusts in order to develop 
recommendations for patient follow- up care.
METHODS
The aim of this study was to explore experiences of 
patients’ with pleural mesothelioma of follow- up care 
in three NHS Trusts in the South of England. Specific 
objectives were to gain a detailed understanding of 
current mesothelioma follow- up care pathways and 
processes, compare findings across different trusts and 
to develop recommendations to propose a revised, 
patient focused, follow- up care service. The study was 
qualitative in design and comprised three interlinked 
phases: a documentary analysis, interviews and consulta-
tion meetings. Altheide and Johnson’s Analytic Realism 
(1994) theoretical framework was used to guide the 
data analysis and writing process. This conceptual 
framework is founded on the view that the social world 
is an interpreted world and that in order to increase 
scientific validity, reflexive qualitative research must pay 
attention to issues such as the research context, inter-
actions between researchers and participants and the 
perspective through which the research is framed.23 
These considerations were central to the research 
process, enabling data to be generated that built under-
standing of the population under study, while paying 
attention to the local context in which the research was 
perceived and understood.
The Consolidated criteria for Reporting Qualitative 
research 2.0 checklist was adhered to.
Patient and public involvement
Patients and public involvement (PPI) representatives 
were involved in the study design process and were invited 
members of the study’s Steering Group Committee. The 
research questions and outcome measures were reviewed 
and approved by three PPI representatives, who provided 
feedback on the original grant application, where aspects 
of the study design were critiqued, as well as reviewing 
subsequent study documents, such as participant infor-
mation leaflets and interview topic guides. PPI members 
were involved in the conduct of the study throughout, 
through attendance at three Steering Group meetings 
(held every 6 months), where issues relating to the study 
process, including recruitment issues, were debated 
and agreed. Through the study’s consultation meetings, 
patients and carers also helped to prioritise the research 
findings, coproduce the study recommendations and 
help agree plans for dissemination of the findings to the 
wider mesothelioma community.
Phase 1: documentary analysis of service documents
Reports, guidance, policy and patient- focused docu-
ments relating to mesothelioma follow- up care pathways 
were accessed by the researchers via mesothelioma or 
lung cancer nurse specialists at each trust. The docu-
ments were manually reviewed by the researchers (ZD, 
CH), and summarised to establish what services were in 
place, how they were structured, resourced and managed, 
as well as identifying any key enablers or barriers to the 
successful running of the services. Findings were charted 
using a framework approach to allow comparisons across 
the three trusts.24 Findings from the documentary anal-
ysis were used to inform and contextualise phase 2 of 
the study, allowing the research team to: ask pertinent 
questions during the interviews that were relevant to the 
different settings and care pathways in place; identify and 
interpret nuanced similarities and differences between 
the three trusts; and develop and refine the framework 
matrix.
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Phase 2: semistructured interviews with patients with 
mesothelioma
Individual, face- to- face semistructured interviews with 
patients with pleural mesothelioma at the partici-
pating trusts were conducted by a female, postdoctoral 
researcher (ZD) with a specialist interest in mesothe-
lioma care, to capture a rich range of perspectives and 
explore, in depth, their experiences of follow- up care.25 26 
The researcher and participants had not met prior to 
the interviews and participants had no prior knowledge 
of the research interviewer. Participants were sampled 
purposively, according to the hospital trust where they 
had been treated and by gender to ensure variation in the 
study population. One of the three participating trusts 
treated 30–40 patients with new mesothelioma each year, 
whereas the other two trusts treated 15–20. Therefore, our 
sampling strategy accounted for this, by recruiting over 
50% of participants from the largest treating site. Based 
on the maximum number of new cases of mesothelioma 
across the three trusts totalling 80, we felt a sample size of 
20 would provide us with a sufficient breadth and depth 
of data to reach saturation. Participants aged 18 years and 
over, who had been diagnosed with mesothelioma at one 
of the participating trusts and were in follow- up, were 
eligible to take part and were recruited by mesothelioma 
or lung cancer nurse specialists. Patients who were non- 
English speaking, unable to provide written informed 
consent, or whom the nurse specialists felt might find 
participation too distressing, were excluded. Eligible 
patients were posted an invitation letter, participant infor-
mation leaflet, and study opt out form. After 2 weeks, any 
eligible patients who had not opted out were contacted 
by the researchers and, if they were happy to partic-
ipate, a time, date and place to carry out the interview 
was organised, either at participants’ own homes or in a 
private room at the participating university, depending 
on patient preference. All participants provided written 
informed consent prior to the interview and completed 
a short, demographic form. Interviews were guided by 
an interview topic guide, which explored experiences of 
patients with mesothelioma of follow- up care, including 
the type, duration and frequency of support received 
from healthcare professionals. Satisfaction with care, rela-
tionships with healthcare professionals, perceived value 
of follow- up pathways, challenges or barriers to accessing 
support and any suggestions for improvement were also 
explored. Each interview was digitally recorded and lasted 
approximately 1 hour. Each participant was interviewed 
once only.
Using Altheide and Johnson’s Analytic Realism (1994) 
theoretical framework to guide the data analysis process,23 
the interview data were thematically analysed using the 
framework method to allow assessments and interpreta-
tions of the thematic relationships across and within cases 
to be made.24 Data were inputted and managed via Micro-
soft Excel. All transcripts were coded by a member of the 
research team (ZD), with three transcripts double coded 
by two other members of the research team (CH, HW). 
Interview participants were not asked to comment on the 
interview transcripts. The analytical framework enabled 
themes to be identified that were derived from the data; 
these were discussed and agreed by the research team at 
regular study meetings. Interview findings were presented 
at the phase 3 consultation meetings.
Phase 3: consultation meetings with stakeholders
Three consultation meetings with key stakeholders 
(n=35): mesothelioma specialist nurses (n=9), patients 
with mesothelioma and carers (n=11), local clinical 
commissioning group members, comprising both clinical 
(respiratory consultants, oncology consultants, clinical 
nurse specialists) and non- clinical staff (n=15), were held 
1–3 months after interview data collection completion to 
discuss and prioritise the phases 1 and 2 findings. Any 
overarching themes that had been developed from the 
interview data were discussed and priority setting activities 
were undertaken to examine their relevance and impor-
tance to patients. Each consultation meeting lasted 1–3 
hours; refreshments were provided and travel expenses 
were reimbursed. Over the course of the meetings copro-
duced recommendations for policy and practice were 
developed between the researchers and the stakeholders. 
Key discussion points were charted using a framework 
approach to allow the priorities of stakeholders to be 
compared and recommendations to be drafted. This 
enabled a preferred, patient focused, mesothelioma 
follow- up service to be proposed that was underpinned 
by a rigorous evidence base, as well as being collaborative 




Each trust had clearly defined mesothelioma treatment 
and follow- up pathways in place (table 1).
However, these pathways were not always distinct from 
the lung cancer care pathway. One trust had established a 
regional mesothelioma multidisciplinary team meeting in 
addition to its regular lung cancer multidisciplinary team 
meeting, but attendance at this meeting was variable. A 
wide range of healthcare professionals were involved in 
the mesothelioma care pathways at each trust; however, 
there was variation with regard to whether patient care 
was led by respiratory or oncology teams. In addition, only 
one trust had a mesothelioma specialist nurse based on 
site. Although the mesothelioma specialist nurse covered 
all three trusts, the majority of their caseload fell under 
the trust at which they were based. All trusts provided 
patient information packs to patients which included leaf-
lets about mesothelioma, details of key contacts and an 
asbestos disease support charity that provided assistance 
with accessing benefits and entitlements. Across the trusts 
there was variation in the level of information provided to 
patients about research and clinical trials, as well as how 
to access local support groups. Two of the trusts treated 
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15–20 newly diagnosed patients per year, while the third 
treated 30–40 per year; all trusts covered large geograph-
ical areas and had primary and satellite clinic sites for 
patient treatment and follow- up visits.
Interviews
The demographic characteristics of participants are 
presented in table 2.
Thirty- two eligible patients agreed to be contacted by 
the research team, the majority of which came from the 
tertiary centre (n=20). Of these, 21 consented to take 
part in the interview, nine declined, one was too unwell 
to participate and one had died; this was sufficient to 
reach data saturation. The majority of participants were 
white, male, aged 70–79 and had received their diagnosis 
within the last 18 months. Most participants had received 
chemotherapy and/or surgery (n=17, 81.0%); however, 
two (9.5%) reported not receiving any treatment or 
support, and two (9.5%) reported receiving symptomatic 
support only.
Thematic analysis identified five overarching themes 
relating to patients’ experiences and views of follow- up 
care services: People, Process, Place, Purpose and Percep-
tion of Care. The first four themes aligned with distinct 
aspects of the follow- up care pathway and were weighted 
differently by participants in terms of their importance 
and the impact they had on their overall perception of 
care. Thus, the final, fifth theme ‘Perception of Care’ 
underpins the first four themes and represents the extent 
to which the accumulation of these themes impacts on 
patients with mesothelioma perceived quality and satisfac-
tion with follow- up care. The five themes are expanded 
on below, with relevant, illustrative quotes presented in 
table 3.
People
Participants identified the relationships they developed 
with healthcare professionals throughout their diagnosis 
and treatment as being central to their experience and 
level of trust they had in their follow- up care provision. 
Open communication and continuity of care, particularly 
with specialist nurses and lead consultants, were partic-
ularly important; having a named clinician, seeing the 
same clinicians at each appointment and having sufficient 
consultation time were viewed as key to this. The role of 
family and friends in providing additional practical and 
emotional support throughout the care pathway was also 
illuminated. Participants varied with regard to their will-
ingness to engage with support groups and their associ-
ated benefits. However, participants who did belong to 
support groups perceived them to be important sources 
of support.
Process
Across the trusts, participants were generally satisfied with 
the clinical environment they were cared for in. They 
commented that efficient, flexible processes associated 
with automated and routine systems, such as appointment 
Table 1 Summary of documentary analysis findings
Trust A Trust B Trust C
Type of hospital/trust District general hospital Tertiary centre District general hospital
No. of patients with 
new mesothelioma
15–20 per year 30–40 per year 15–20 per year
Clinical team Lung cancer MDT:
respiratory, oncology, thoracic, 
palliative, radiology, pathology, 
lung cancer CNS
Lung cancer MDT and regional 
mesothelioma MDT:
pleural/respiratory, oncology, 
thoracic, palliative, radiology, 
pathology, lung cancer CNS, 
mesothelioma specialist nurse
Lung cancer MDT:
respiratory, oncology, thoracic, 
lung cancer CNS, pleural nurse
Pathway Oncology led
6–8 weekly follow- up
If treatment discontinued referral 
to community/palliative care
Respiratory led
2–3 monthly follow- up 
depending on symptom control
Oncology led
Monthly follow- up
If treatment discontinued 




Patient information leaflet (lung 
cancer),
Understanding mesothelioma
Asbestos disease charity support
Team contact details




Asbestos disease charity 
support





Symptom management leaflets 
Asbestos disease support 
charity




CNS, Clinical Nurse Specialist; MDT, multi- disciplinary team.
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booking, waiting times, telephone helplines, routine scans 
and tests and moving between and across services, helped 
make the follow- up care pathway easier to navigate and 
more responsive to their individual needs and circum-
stances. However, when administrative or procedural 
errors occurred, some participants reported distress.
Place
Practical and logistical factors associated with hospital 
and clinic locations, parking and access were identified as 
causing potential frustration or distress. However, despite 
often being irritated with these issues, most participants 
accepted that these problems were not specific to their 
mesothelioma care pathway; therefore, they did not 
substantially impact on their overall perception of care.
Purpose
Participants identified a number of key care priorities 
and informational needs that were highly motivating 
factors for engaging with follow- up care. The main driver 
was a desire to monitor disease progression and symptom 
management, something which led to a desire for regular 
follow- up consultations with care teams. Equally, discus-
sions around treatment options, whether to continue 
with treatment and when to seek out new, private and/
or experimental treatments were important markers 
within the follow- up trajectory and the ease with which 
these were discussed was linked closely to the level of trust 
participants had in their care team. Follow- up care was 
also associated with a desire to gain more information 
about mesothelioma in terms of prognosis, care pathways, 
benefits and entitlements and any planned transitions to 
linked services such as community and palliative care 
teams. Participants reported variations in their baseline 
knowledge of mesothelioma and the subsequent level 
of information they were provided with from their care 
teams.
Perception of care
Overall, most participants viewed the treatment and 
follow- up care they had received for mesothelioma posi-
tively. Generally, participants who reported the most 
consistent healthcare contacts also reported high levels 
of trust in their named consultant and specialist nurse, 
and a resulting satisfaction with care. This level of trust 
also impacted on the treatment choices of some partici-
pants, with those who described less trusting relationships 
being more likely to seek second opinions, or treatments 
from alternative NHS providers and the private sector. 
However, some participants who reported suboptimal 
care were less confident or unaware of the other options 
available to them, such as how to access advice and 
support from a specialist mesothelioma nurse.
Consultation meetings
The findings that emerged from the interview data were 
reviewed at the consultation meetings and barriers, facili-
tators and potential solutions to any challenges identified 
were discussed and prioritised, in relation to the overall 
perceived impact on care (table 4).
From this, a draft set of recommendations were devel-
oped in relation to the preferred structure of the clin-
ical care team, the timing and content of information 
provided to patients, the integration of secondary, palli-
ative and community care services, and links with wider 
support services. The full set of recommendations will 
be reported elsewhere, but figure 1 sets out the six main 
recommendations arising from the consultation meet-
ings. The primary recommendation was for all patients 
with mesothelioma to have access to a specialist meso-
thelioma team within a streamlined mesothelioma care 




  Male 15 (71.4)
  Female 6 (28.6)
Age group (years)
  60–69 2 (9.5)
  70–79 15 (71.4)
  80–89 4 (19.0)
Ethnic group
  White 21 (100)
NHS Trust
  Trust A 6 (28.6)
  Trust B 11 (52.4)
  Trust C 4 (19.0)
Time since diagnosis (months)
  1–6 4 (19.0)
  7–12 4 (19.0)
  13–18 5 (23.8)
  19–24 1 (4.8)
  25–29 1 (4.8)
  30–36 0 (0)
  >36 6 (28.6)
Treatment*
  Chemotherapy 12 (57.1)
  Radiotherapy 5 (23.8)
  Surgery 9 (42.9)
  Immunotherapy 2 (9.5)
  Symptom support 8 (38.1)
  Psychological support 2 (9.5)
  Hospice care 1 (4.8)
  Research trial 2 (9.5)
  None 2 (9.5)
NHS, National Health Service .
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pathway. The recommendations also led to the concep-
tual development of our ‘pyramid of care’ (figure 2), 
following input from the key stakeholders. The pyramid 
of care identifies the core support structures required 
to develop and sustain a robust and streamlined meso-
thelioma care pathway. The pyramid of care places a 
named mesothelioma specialist nurse and mesothelioma 
specialist respiratory consultant at the top of the pyramid, 
underpinned by expertise and resource from the wider 
multidisciplinary team. It emphasises the importance 
of iterative communication channels between different 
clinical and support services to promote patient centred, 
joined up care.
DISCUSSION
Our findings and newly developed recommenda-
tions have illuminated the need for patients with 
Table 3 Key themes and illustrative quotes from interviews
Theme Subtheme Quotation
People Communication The reason those Meso nurses are there is they have got the time to learn more about it 
and keep [us] on track with what’s going on (Male, 60–69, Trust B)
Continuity of care I don’t feel as though I’ve been cast off. It’s obviously going to be a different kind of 
approach [in palliative care] but…we’ve still got that link with [the consultant and the 
Specialist Nurses] (Female, 70–79, Trust A)
  Family and friends I don’t know how people could cope, really. If there was no family around and I was the 
way I was now, I still don’t think I’d be the same person (Male, 70–79, Trust A)
Support groups (We went] to find out more about it and…how other people are dealing with it. And that 
was so important (Female, 70–79, Trust A)
Process Administration The professionals have been very good, the surgeon and the registrar and other people 
that I’ve seen…It’s admin that really drives me crazy. (Male, 70–79, Trust A)
  Accessibility We need to have a phone number where we can make the call when it’s necessary. And 
we know that help is available. (Male, 70–79, Trust A)
  Delays Scanxiety, when you get anxious after you’ve had a scan what the results are…there is, 
unfortunately a general delay across the whole board (Male, 60–69, Trust B)
  Falling through the 
system
You fell in a bit of a crack for a while, because, although with oncology we declined it…
but somehow we hadn’t got it back respiratory care. (Female, 70–79, Trust C)
Place Distance, location, 
parking
I don’t drive. Well, friends have said I’ll take you, but of course, they’re all about my age 
and they might have problems of their own (Female, 70–79, Trust A)
Purpose Monitoring I’ve got peace of mind, knowing that every so many weeks I’m going to see the 
consultant and they can monitor the progress and that’s all I really need…How it’s 
progressing…How to deal with the pain when the time comes” (Male 70–79,Trust A)
  Treatment options/
decisions
I’d always try those things [treatments]…You’ve got to…Because there’s always 
something new coming out and that’s what you bank on…That’s what you’ve got to hope 
for all the time and just go with whatever’s going.” (Male, 70–79, Trust B)
  Understanding 
mesothelioma
The horrible thing is that there’s going to come a point when I may start to go. You don’t 
even know the process of dying from this disease. Is it sudden? Or is it progressive? I 
don’t think anybody can [tell me].” (Male, 70–79, Trust A)
  Understanding 
pathways
I’m perfectly realistic. I know I’m going to die. I just want some sort of realistic 
understanding…that I’m living by myself. I’m 75 years old…The hospice group who have 
been extremely good, they don’t have accommodation. (Male, 70–79, Trust A)
  Understanding 
benefits and 
entitlements
Once I was diagnosed, I was immediately put in touch with a charity…They were very, 
very helpful…looking into benefits…compensation…solicitors…They…know the system, 
so that helps. (Male, 60–69, Trust B)
Health literacy We know how to use information…A lot of people… Could be treated without actually 
having the ability to say, what’s going on? (Male, 70–79, Trust C)
Perception of 
care
Satisfaction I’ve been very satisfied with the team…They’ve been very good to me…The follow- up 
care that I’ve had…They’ve kept an eye on me. (Male, 80–89, Trust B)
Trust We trusted [the consultant] implicitly that if there was [another treatment option], they 
would have said. (Female, 70–79, Trust A)
Second opinions You won’t get the help, once you’ve had the allowed treatment…You have to find it 
somewhere else…Literally, find a trial or sometimes I understand some of the more 
specialist trusts…trying to find new solutions. (Male, 60–69, Trust B)
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mesothelioma to have access to a specialist, streamlined 
mesothelioma care pathway, to ensure the delivery of 
consistent, patient centred care. While this provision of 
care should be centred around, where possible, meso-
thelioma specialist nurses and respiratory consultants, 
input from multidisciplinary team members is essential 
for underpinning the patient follow- up pathway with 
appropriate resources which can be accessed from the 
point of diagnosis onwards, to promote joined up care 
(figure 2). The benefits of being able to access a specialist 
Table 4 Needs, barriers and solutions identified through consultation meetings




People Early access to 
mesothelioma specialist 
team
Continuity of care and 
integrated respiratory and 
follow- up pathways
 ► Lack of resources
 ► Existing organisational 
structures and referral 
processes
 ► Lack of patient knowledge 
of pathway





Shared care approach with 
respiratory led follow- up
High
Purpose Information about range 
of treatment options and 
pathways
Clear and responsive 
follow- up schedule
 ► Lack of consistency 
in range of treatments 
available
 ► Lack of knowledge 
of options available 
(patients and healthcare 
professionals)
Mesothelioma nurses and 
consultants should provide 
specialised information
Provision of additional 
resources to patients
Clear signposting to specialist 
support available
Regular follow- up based on 
patient need
High
Place Ease of access  ► Geographical barriers
 ► Transport/parking
 ► Differing levels of support 
at home
 ► Limited understanding of 
entitlements
Signposting to increase 
awareness of options with 
regard to access and support 
services
Flexibility when arranging 
appointments
Low
Process Joined up service provision 
between secondary, 




Continuity of care when 
transferring in and out of 
different services
 ► Differences in referral 
pathways and accessing 
palliative care/community 
services
 ► Lack of resources
 ► Patient awareness 
of services available 
at different trusts 
Administrative issues
Mesothelioma specialist 
nurse primary point of contact 
between secondary, palliative 
and community care
Patients provided with options 
for contact and communication
Continuous contact with 
mesothelioma specialist nurse 
throughout pathway
Medium
Figure 1 Key recommendations for follow.
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mesothelioma team have clear advantages for patients. 
For example, rapid and appropriate access to interven-
tions, such as the insertion of indwelling catheters and 
targeted pain management, can help alleviate symptoms 
caused by pleural effusions and empyema. Addressing 
these long- term symptomatic management and palliative 
care concerns is something that can be anticipated and 
effectively resolved through close working with respira-
tory consultants who have expertise in this area, along-
side comprehensive follow- up support and monitoring 
from mesothelioma specialist nurses. However, when this 
is not feasible, oncology led or formalised shared care 
approaches should also be considered.
Additionally, the current limited mesothelioma 
specialist nurse resource20 highlights the need for appro-
priate training and education to be provided to lung 
cancer nurse specialists, palliative and community care 
teams by mesothelioma specialist nurses, to ensure needs 
and requirements of patients with mesothelioma are 
being met consistently and comprehensively throughout 
their follow- up pathway.
In line with British Thoracic Society guidelines,2 17 
patients with mesothelioma must be equipped with neces-
sary levels of information, including accessing clinical 
trials opportunities, to inform their decision- making. 
Currently, across different hospital trusts, patients are 
exposed to variation in the type, level and range of infor-
mation that is provided to them, resulting in an inequity 
of opportunity around care and treatment provision. 
While there may be variations in patients’ health literacy 
and information seeking,27 clinicians must assess under-
standing, as well as the level and type of information that 
individual patients wish to receive. This may be facilitated 
through the presence of a mesothelioma/lung cancer 
specialist nurse in follow- up consultations.
The omnipresent concerns expressed by patients with 
pleural mesothelioma about their future health and how it 
will be managed can be mediated through the provision of 
regular follow- up consultations with a named care team. The 
frequency of these consultations may vary depending on 
patient need, symptom severity and prognosis, but should 
be reviewed regularly in line with patient care priorities. 
Similarly, early referral to palliative care services, along with 
the provision of a clear rationale as to why it is necessary 
may help to assuage feelings of uncertainty. An iterative rela-
tionship between secondary, palliative and community care 
services should be maintained to aid communication and 
specialist support at all levels.
A key study strength is that, to our knowledge, it is the first 
to explore, in depth, experiences of patients with pleural 
mesothelioma of follow- up care pathways across different 
hospital trusts with different organisational systems and 
processes. This has enabled comparisons in patient experi-
ence to be mapped out and recommendations developed. 
The twenty- one interview participants had a wide range of 
demographic characteristics, increasing the transferability 
of our findings, while the consultation meetings undertaken 
verified and prioritised these findings, ensuring that any 
recommendations developed were practical, feasible and 
of value to patients. A study limitation is that although the 
participant population was representative of the wider meso-
thelioma population in terms of age, ethnicity and gender, 
six interview participants (29%) had been diagnosed with 
mesothelioma over 36 months previously, which is substan-
tially longer than the median survival time of 8–14 months. 
Moreover, a substantially higher proportion of participants 
Figure 2 Mesothelioma ‘pyramid of care’ patient support structure.
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in this study received a form of active treatment (81%) than 
was found in the most recent National Mesothelioma Audit 
(48%).19 The high levels of patient satisfaction identified in 
the current study may in part be attributable to the higher 
level of specialist care received by this group.
Little literature exists on the patient experience of 
mesothelioma follow- up care.12 However, there is growing 
interest in this area, with the recent Mesothelioma 
Outcomes Research and Experience (MORE) survey 
collecting patient with mesothelioma data about what can 
be done to enhance the patient experience.5 In addition, 
a phenomenological study exploring the lived experience 
of people with mesothelioma found that the communica-
tion pathways between patients and healthcare providers 
were central to the patient experience11; this correlates 
strongly with our findings. However, Walker’s study was 
based in the USA, whereas our study examined the UK 
healthcare system, focusing on the role of mesothelioma 
specialist care teams and offering practical solutions for 
optimising care outcomes.
Our findings have important implications for clinicians 
and policy- makers and have led to a number of recommen-
dations being produced. Clinicians must consider what 
changes to practice can be made within their organisations 
to facilitate them, something that will require close working 
with other sectors of the health service. Policy- makers need 
to consider how resources can be optimised and restructured 
to ensure that a bespoke mesothelioma care pathway is real-
ised within secondary care services. This may mean lobbying 
to improve the support structures and services available to 
patients (figure 2) and ensuring that they have access to the 
full range of treatment options available, regardless of the 
location of their care.
Our study has illuminated many important questions 
relating to how patients with pleural mesothelioma expe-
rience care and has highlighted the need for consistent 
input from clinical teams. However, only a relatively 
small number of patients with mesothelioma are seen 
by respiratory and oncology teams each year, compared 
with patients with lung cancer and this may impact on the 
extent to which clinicians use the evidence base to inform 
their treatment decision- making. Other factors such as 
prior experience, advice from colleagues, adhering to 
the status quo and input from the multidisciplinary team 
may be influencing factors. Future research to unpick 
these decision- making processes would help ensure that 
the patient experience is underpinned by a rigorous, and 
consistently upheld, evidence base.
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